gaining access to a broad, multi-indication pipeline. The team manages an extensive portfolio spanning oncology, cardiovascular disease, and dermatology, combining novel programmes with high-quality, previously abandoned assets that it reevaluates and repositions. From a business and financing perspective, DISIT Biotech applies the same discipline and transparency. The company is currently in an active financing round, aimed at executing a Phase IIb clinical trial in an orphan indication, while completing preclinical development and initiating the clinical trial of a first in class drug in oncology. As part of this approach, DISIT Biotech took the proactive decision to mandate a full, independent due diligence of its lead project by Alira Health. “A clear example is our decision to request an independent, external due diligence of our lead programme by Alira Health,” shared Rafael González. “We chose to approach investors and partners with our strengths and weaknesses fully on the table, supported by an externally validated assessment of probability of success and potential returns. In short, our partners work with a company that is ambitious and pioneering, but also radically transparent, systematically derisking its pipeline and aligning fully with long-term value creation rather than short-term optics.” Of course, in order to conduct pioneering research and disruptive science for patients, it is imperative that DISIT Biotech operates with a team that feels respected, inspired, and constantly challenged to grow. The company emphasises structured knowledge sharing, with regular cross-functional project reviews, journal clubs, and case discussions that align business strategy with biology, chemistry, and clinical thinking. Behind everything DISIT Biotech does – from its model of derisking abandoned R&D to its transatlantic operating structure – there are very specific patients the team is working to support. This includes patients with systemic sclerosis and morphea, for whom effective, mechanism-based treatments remain limited, as well as oncology patients in need of more effective and bettertolerated therapies. Ultimately, DISIT Biotech aims to position itself as the go-to partner for high-potential, previously abandoned assets requiring significant scientific, clinical, and business redesign. By leveraging high-quality science and a strong transatlantic platform, DISIT Biotech will continue to deliver meaningful therapeutic options to patients living with high unmet medical needs. “In summary,” concluded Rafael González, “2026 is about turning recognition into execution: advancing our most mature programmes through critical clinical milestones, closing a strong financing round, and building a solid data and IP foundation that supports sustainable longterm value creation. Our recognition as Spain’s Most Pioneering Disruptive Biotech Company 2026 is not just about ambition or geography; it is about redefining what is possible for patients who cannot afford to wait.”
RkJQdWJsaXNoZXIy MTUyMDQwMA==